Temozolomide in Patients with High Grade Gliomas

The incidence of central nervous system neoplasias ranges from 3.8 to 5.1 cases per 100,000 inhabitants. First-line treatment of brain tumors consists of surgery associated with radiotherapy, and followed or not by chemotherapy. When used as an adjuvant therapy after surgery and radiotherapy, chemot...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Oncology 2000-01, Vol.59 (3), p.181-186
Hauptverfasser:	Brandes, Alba Ariela, Pasetto, Lara Maria, Vastola, Francesca, Monfardini, Silvio
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic agents Antineoplastic Agents, Alkylating - therapeutic use Biological and medical sciences Central Nervous System Neoplasms - drug therapy Chemotherapy Clinical Trials, Phase I as Topic Clinical Trials, Phase II as Topic Dacarbazine - analogs & derivatives Dacarbazine - therapeutic use Glioma - drug therapy Humans Medical sciences Pharmacology. Drug treatments Review
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The incidence of central nervous system neoplasias ranges from 3.8 to 5.1 cases per 100,000 inhabitants. First-line treatment of brain tumors consists of surgery associated with radiotherapy, and followed or not by chemotherapy. When used as an adjuvant therapy after surgery and radiotherapy, chemotherapy prolongs the time to progression and the median survival time. At relapse, chemotherapy is the common therapeutic approach. In recent years, new drugs for the treatment of brain tumors have been tested, and some of them, such as temozolomide, are very promising.
ISSN:	0030-2414 1423-0232
DOI:	10.1159/000012158